BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 29428426)

  • 1. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.
    Tarhini M; Fayyad-Kazan M; Fayyad-Kazan H; Mokbel M; Nasreddine M; Badran B; Kchour G
    Microb Pathog; 2018 Apr; 117():23-26. PubMed ID: 29428426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial.
    Xie Y; Pan X; Li Y; Wang H; Du Y; Xu J; Wang J; Zeng Z; Chen Y; Zhang G; Wu K; Liu D; Lv N
    J Antimicrob Chemother; 2018 Jun; 73(6):1681-1687. PubMed ID: 29596646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
    Korman MG; Bolin TD; Nicholson FB; Engelman JL
    Helicobacter; 1998 Sep; 3(3):202-5. PubMed ID: 9731992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.
    Hu JL; Yang J; Zhou YB; Li P; Han R; Fang DC
    Saudi J Gastroenterol; 2017; 23(5):275-280. PubMed ID: 28937021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 12. Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait.
    Alboraie M; Saad M; Al-Ali J; Malik M; Asem N; Schmidt I; Alfadhli AA
    Arab J Gastroenterol; 2015; 16(3-4):131-5. PubMed ID: 26611765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Eradication of Helicobacter pylori in peptic ulcer and chronic gastritis. A randomized clinical trial].
    Rodríguez Hernández H; Sánchez Anguiano LF; Quiñones E
    Rev Gastroenterol Mex; 1998; 63(1):21-7. PubMed ID: 10068745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Helicobacter pylori infection: a review of the world literature.
    van der Hulst RW; Keller JJ; Rauws EA; Tytgat GN
    Helicobacter; 1996 Mar; 1(1):6-19. PubMed ID: 9398908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
    Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
    Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
    Aktaş B; Başyiğit S; Yüksel O; Akkan T; Atbaşı ST; Uzman M; Yılmaz B; Şimşek G; Nazlıgül Y
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):769-75. PubMed ID: 25919773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
    Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sucralfate as an alternative to bismuth in quadruple therapy for Helicobacter pylori eradication.
    Korman MG; Bolin TD; Engelman JL; Pianko S
    Helicobacter; 1997 Sep; 2(3):140-3. PubMed ID: 9432342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.